Shionogi and Co Ltd

Trending Articles

  1. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
  2. CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
  3. ISPE announces 2024 Facility of the Year Awards category winners The awards programme recognises pharmaceutical companies that are the 'best' in the industry for innovation, operations, digitalisation, supply chain and social impact
  4. Tabletability, compactability and compressibility: What’s the difference? To patients and consumers, tablets are a simple and convenient dosage form, but the science behind compressing a block of particles or granules into a single tablet can be...
  5. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

Related Content

Drug Delivery

Akili and Shionogi sign deal to expand digital medicine to Asia

Treatment for ADHD and autism dosed by an action video game is under review by the US FDA and has already found a distributor for Japan and Taiwan
Media

Positive Phase III results in high-risk patients expected to support FDA review process for Roche’s Xofluza

Following the recent news that Roche has announced positive top-line results from its Phase III trial for influenza drug, Xofluza, Tom Moore, Senior Healthcare Analyst at GlobalData, a leading data and analytics company, offers his view
Digital

Shionogi modernises product quality management in the cloud

Pharmaceutical company in Japan unifies product quality management processes across global stakeholders
Research & Development

Egalet terminates collaboration with Shionogi

Gains worldwide rights to Phase ! abuse-deterrent, extended-release hydrocodone product candidate
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

New NCEs focus on cancer and orphan diseases

The number of NCEs approved in Europe increased again in 2014, with the spotlight on cancer drugs and treatments for unmet medical needs. Dr Sarah Houlton reviews the new entrants
You need to be a subscriber to read this article.
Click here to find out more.

Japan funds R&D for tropical medicines for poor countries

Japanese drug manufacturers are increasing their efforts to ensure more accessible and effective medicines are brought to the developing world
Research & Development

Egalet to collaborate with Shionogi to develop abuse-deterrent oral hydrocodone opioid product candidates

Will receive upfront and milestone payments plus potential royalties on net sales
Subscribe now